Loading...
•
Dec 31, 2021
Standard Biotool Q4 2021 Earnings Report
Announced fourth quarter and full year financial results.
Key Takeaways
Fluidigm Corporation reported a total revenue of $38.3 million for Q4 2021, compared to $44.6 million for Q4 2020. Base product and service revenue (excluding COVID-19 testing revenue) increased 13.5 percent to $35.3 million. The GAAP net loss for the quarter was $9.4 million, compared to a GAAP net loss of $18.0 million for the same period last year.
Total revenue was $38.3 million for the quarter ended December 31, 2021, compared with $44.6 million for the fourth quarter of 2020.
Base product and service revenue (excluding COVID-19 testing revenue) increased 13.5 percent to $35.3 million, compared with $31.1 million in the same period last year.
GAAP net loss for the quarter was $9.4 million, compared with a GAAP net loss of $18.0 million for the fourth quarter of 2020.
Non-GAAP net loss was $0.8 million for the quarter, compared with a non-GAAP net loss of $9.8 million for the fourth quarter of 2020.